REDWOOD CITY, Calif.–(BUSINESS WIRE)–#anthem–Proteus Digital Health™ announced today that Joseph Swedish, the
Executive Chairman of Anthem Inc., (NYSE: ANTM) has joined its Board of
Anthem, Inc. is the nation’s leading health benefits provider. Mr.
Swedish was named Anthem’s President and Chief Executive Officer in
March 2013 and was appointed to the additional role of Chairman of the
Board in December 2015. He became Executive Chairman in 2018.
He has more than two decades of healthcare leadership experience as the
CEO for several major health systems and has been at the forefront of
the industry’s efforts to utilize advances in information technology for
electronic health records, data analytics, provider enablement tools and
consumer solutions. Mr. Swedish holds a bachelor’s degree from the
University of North Carolina at Charlotte and a master’s degree in
health administration from Duke University.
“Proteus has created a compelling solution to a problem that has plagued
the pharmaceutical industry for decades: achieving outcomes in the real
world that match those in clinical trials,” said Mr. Swedish. “Digital
Medicines accurately measure medication ingestion and key health
metrics. They present an opportunity for companies to engage in
value-based contracts, where reimbursement for the drug is tied to a
Mr. Swedish’s other board affiliations include: CDW, a leading provider
of technology solutions to business, government, education, and health
care; and IBM, one of the world’s largest technology companies with
businesses in computer hardware, middleware and software, data hosting
and consulting services.
Andrew Thompson, Proteus Digital Health co-founder and Chief Executive
Officer commented: “We have demonstrated widespread patient acceptance
of Digital Medicines and successfully integrated them into physician
workflows, improving outcomes. Our next challenge is to show that
Digital Medicines enable value-based contracting, wider patient access
and a more sustainable pharmaceutical industry business model that
aligns the interests of innovators, patients and payers. No one is more
qualified to help us succeed with this final innovation step than Joe
About Proteus Digital Health™
In November 2017, the FDA approved the first New Drug Application (NDA)
for a Digital Medicine: Otsuka’s Abilify Mycite ®. This approval opens a
new path for innovation in the pharmaceutical industry based on silicon
and software. Proteus Digital Health created the technology that enables
These offerings include widely used drugs, formulated so they
communicate when they have been swallowed; a wearable patch that detects
medicines and captures physiologic response; mobile applications to
support patient self-care and physician decision-making; and data
analytics to serve the needs of health system managers.
Digital Medicines are in commercial use in the United States. Data from
both randomized clinical trials and real-world use demonstrate that
patients have significantly improved outcomes using Digital Medicines
(for example control of blood pressure) and that these outcomes can be
Proteus Digital Health is privately held by investors that include
Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®,
Otsuka®, Oracle®, and ON Semiconductor®. Further information is
available at: www.proteus.com.
Connect with us on Twitter @ProteusDH.
Proteus Digital Health, Inc.
Emily Fox, +1 650-637-6240